Login to Your Account



Multiple Products, Indications in Pain

Xenon, Roche Deal May Reach $646M; Details Under Wraps

By Anette Breindl
Science Editor

Tuesday, January 10, 2012
Canadian biopharma Xenon Pharmaceuticals Inc. has nabbed a deal that could be worth more than $600 million. The collaboration with Roche Holdings AG member Genentech Inc. intends to discover and develop compounds and companion diagnostics for the treatment of pain.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription